Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Irritable Colon Clear all
Terminated Phase 4 Interventional Results available

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

NCT01337609
View directory record Official record
Conditions
Major Depressive Disorder, Irritable Bowel Syndrome
Interventions
Ganeden BC30, Placebo (sugar pill), Ganeden BC30, Placebo (sugar pill)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Burlington, Massachusetts • Westborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 25, 2026, 6:55 AM EDT
Suspended Phase 2 Interventional

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

NCT01076699
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo
Drug
Lead sponsor
Revogenex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chevy Chase, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

NCT00583128
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
AST-120, Celphere® CP-305
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Not applicable Interventional Results available

Gulf War Digestive Health Study

NCT00680836
View directory record Official record
Conditions
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 72 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01340053
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
RDX5791
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
San Diego, California • Jupiter, Florida • Pinellas Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

NCT02686138
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
117
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome

NCT01624610
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dietary intervention
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

NCT00810368
View directory record Official record
Conditions
Persian Gulf Syndrome
Interventions
Carnosine, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
34 Years to 82 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 25, 2026, 6:55 AM EDT
Enrolling by invitation Phase 3 Interventional

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

NCT05905926
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
27
States / cities
Foley, Alabama • Anaheim, California • Doral, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 6:55 AM EDT
Terminated Not applicable Interventional Results available

Neuromodulation for Children With Cystic Fibrosis Experiencing Chronic Abdominal Pain

NCT05515250
View directory record Official record
Conditions
Cystic Fibrosis, Irritable Bowel Syndrome, Chronic Pain
Interventions
Use of neurostimulation device
Device
Lead sponsor
St. Louis University
Other
Eligibility
11 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain

NCT00554320
View directory record Official record
Conditions
Chronic Pelvic Pain, Interstitial Cystitis, Post Traumatic Stress Disorder, Fibromyalgia, Irritable Bowel Syndrome
Interventions
tDCS
Procedure
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 25, 2026, 6:55 AM EDT
Recruiting Not applicable Interventional

Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children

NCT05730491
View directory record Official record
Conditions
Irritable Bowel Syndrome, Abdominal Pain
Interventions
Social Learning and Cognitive Behavioral Therapy (SLCBT), Attention Education Control
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

NCT01543178
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
open-label rifaximin, double-blind placebo, double-blind rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
293
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Not applicable Interventional

A Study of Hemp Hull WFI for IBS Diarrhea

NCT06028035
View directory record Official record
Conditions
Irritable Bowel Syndrome-bile Acid Diarrhea
Interventions
BB01
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 4 Interventional Results available

Eluxadoline Bile Acid Malabsorption (BAM) Study

NCT03441581
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Eluxadoline
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home

NCT03186872
View directory record Official record
Conditions
Anxiety, Irritable Bowel Disease
Interventions
Digital behavioral program app
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 25, 2026, 6:55 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

NCT02641392
View directory record Official record
Conditions
Crohn's Disease
Interventions
GED-0301, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
San Diego, California • Atlanta, Georgia • Indianapolis, Indiana + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 25, 2026, 6:55 AM EDT
Active, not recruiting Phase 2 Interventional

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

NCT06206265
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
TRYP-0082, Psychotherapy
Drug · Behavioral
Lead sponsor
TRYP Therapeutics
Industry
Eligibility
21 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 25, 2026, 6:55 AM EDT
Not listed No phase listed Observational

Microbial and Human Determinants of the Onset of IBD Flares

NCT05463900
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated, Crohn Disease in Remission
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

NCT00258193
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
MD-1100 Acetate
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2006 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT01130272
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
288
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 25, 2026, 6:55 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, Camlipixant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
112
States / cities
Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 6:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Irritable Bowel Syndrome and Control Volunteers: Diet Challenge

NCT06668922
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Inulin
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

NCT00680693
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness training, Psycho-educational support group for women with IBS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Oct 25, 2026, 6:55 AM EDT